Mydriatics and cycloplegics have limited systemic absorption in the mother, and pose negligible risk to a breastfed infant, especially when used as a single dose for diagnostic or procedural purposes. Risks, arising from infants’ increased anticholinergic sensitivity and decreased milk production, are theoretically increased when used longer-term for uveitis/iritis.
Systemic absorption from eye drops can be minimised by restricting passage into tear ducts immediately after administration (link to technique).
There is no published evidence of safety or milk levels for any of the listed mydriatics and cycloplegics.